Navigation Links
Interleukin Genetics, Inc. to Present at Biotech Showcase 2011
Date:1/4/2011

WALTHAM, Mass., Jan. 4, 2011 /PRNewswire/ -- Interleukin Genetics, Inc. (OTC QB: ILIU) announced today that CEO Lewis H. Bender will present at the Biotech Showcase 2011, taking place at the Parc 55 Wyndham San Francisco, January 10-12, 2011.  The corporate presentation will include a company overview highlighting its business opportunities and is scheduled for Monday, January 10 at 3:45 p.m. in the Mission II room.  

Company management will be available for one-on-one meetings with investors participating in the Biotech Showcase.  A webcast of Mr. Bender's presentation will be available on the Company's Investor Relations section of the Website and will be accessible for 30 days. 

About Interleukin Genetics

Interleukin Genetics, Inc. (OTC QB: ILIU) develops and markets a line of genetic tests under the Inherent Health® brand.  The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics' flagship products include its proprietary PST® genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists, and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, MA and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratories Improvements Act (CLIA).  For more information please visit www.ilgenetics.com.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Interleukin Genetics Licenses its PST(R) Genetic Test to OralDNA Labs
2. Interleukin Genetics and Alticor Agree on Expansion of Distribution Channels for Genetic Tests
3. Interleukin Genetics to Present New Findings at the 11th Cardiovascular Genomics and Atherosclerosis Symposium
4. Interleukin Genetics to Present New Findings on Osteoporosis at the 58th Annual Meeting of the American Society of Human Genetics
5. Interleukin Genetics Reports Third Quarter 2008 Financial Results
6. Interleukin Genetics Appoints Todd Anthony Walker as Vice President, Marketing
7. Interleukin Genetics Receives Notification of Failure to Meet Continued Listing Standard Section 1003(a)(iii)
8. Interleukin Genetics Reports Fourth Quarter and Year End 2008 Financial Results
9. Interleukin Genetics to Present at the 2009 BIO Business Forum
10. Interleukin Genetics Announces Conference Call To Discuss Second Quarter 2009 Results
11. Interleukin Genetics Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... February 17, 2017 According ... by Product (Consumables, Service), Type (Safety, Efficacy, Validation), ... Drug Discovery and Development, Disease-Risk) - Global Forecast ... projected to reach USD 53.34 Billion by 2021 ... a CAGR of 13.8% during the forecast period ...
(Date:2/17/2017)... Feb. 17, 2017  Protagonist Therapeutics, Inc. (NASDAQ: ... its oral peptide drug candidates, PTG-100 and PTG-200, ... European Crohn,s and Colitis Organization (ECCO).  The ECCO ... Spain from February 15 – 18, ... data on Protagonist drug candidates PTG-100 and PTG-200. ...
(Date:2/16/2017)... and GREENWICH, Conn. ... private investment firm focused on venture growth investments ... promotion of Josh Richardson , M.D. to ... investments in biotechnology companies.  He is a board ... important roles in Longitude,s investments in Aimmune Therapeutics, ...
(Date:2/16/2017)... , Feb. 16, 2017   Capricor ... a clinical-stage biotechnology company developing first-in-class biological therapies ... that it has elected to terminate its license ... peptide receptor agonists, including Cenderitide. "Our ... move as we prioritize our efforts to advance ...
Breaking Biology Technology:
(Date:2/13/2017)... 13, 2017 Former 9/11 Commission border counsel ... Janice Kephart of Identity Strategy Partners, LLP, ... Trump,s "Executive Order: Protecting the Nation From Foreign ... "As President Trump,s ,Travel Ban, Executive Order ... essentially banned the travel ban, it is important that ...
(Date:2/9/2017)... Feb. 9, 2017 The biomass boiler market ... the biomass boiler market globally in terms of revenue ... boilers. The market for biomass boilers has been segmented ... application, and country/region. The market based on feedstock type, ... residues, biogas & energy crops, urban residues, and others. ...
(Date:2/8/2017)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its quarter and year ended December 31, 2016. ... million compared to $6.9 million in the same quarter last ... $0.6 million compared to $2.6 million in the fourth quarter ... was $0.5 million, or $0.02 per diluted share, which compares ...
Breaking Biology News(10 mins):